A 55-year-old man comes to the clinic for a routine follow-up. Three months ago, he was diagnosed with primary hyperlipidemia and was started on rosuvastatin. He reports taking his medication daily and has no current complaints. He specifically denies experiencing any muscle weakness, dark urine, abdominal pain, or jaundice. Physical examination reveals no abnormalities. Routine laboratory testing shows the following results:
| Laboratory Parameter | Result | Reference Range |
|---|---|---|
| Aspartate aminotransferase (AST) | 52 U/L | 8-40 U/L |
| Alanine aminotransferase (ALT) | 62 U/L | 7-56 U/L |
| Creatine kinase (CK) | 110 U/L | 22-198 U/L |
Which of the following is the most appropriate next step in management?
- Continue the current medication without changesAnswer
- BDiscontinue the medication immediately
- COrder a right upper quadrant abdominal ultrasound
- DOrder a percutaneous liver biopsy
- EAdd gemfibrozil to the current medication regimen
Answer
Continue the current medication without changes
The correct response is to continue the current medication without changes. Statins competitively inhibit HMG-CoA reductase, and their initiation can frequently cause mild, dose-dependent elevations in hepatic transaminases. According to clinical guidelines, if a patient is asymptomatic and the transaminase levels are less than three times the upper limit of normal, the appropriate management is to continue the statin therapy and monitor. Unnecessary discontinuation deprives the patient of the cardioprotective benefits of the lipid-lowering therapy.
Step-by-Step Solution
Key Concept
Monitoring statin therapy requires recognizing that mild, asymptomatic elevations in transaminases are common and do not require drug discontinuation.